Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Biokin PharmaceuticalBMS

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
ADC / XDCArriVent BioPharma

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
CancerHKG: 2162

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
CancerHKG: 1877

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Show More